Xue Ren1, Ailian Liu1, Lihua Chen1, Shuang Li1, Yue Wang1, Jiazheng Wang2, Qingwei Song1, Sun Peng2, Renwang Pu3, and Yuanfei Li1
1The First Affiliated Hospital of Dalian Medical University, Dalian, China, 2Philips Healthcare, Beijing, China, 3First Affiliated Hospital of Dalian Medical University, Dalian, China
1The First Affiliated Hospital of Dalian Medical University, Dalian, China, 2Philips Healthcare, Beijing, China, 3First Affiliated Hospital of Dalian Medical University, Dalian, China
There are statistically significant differences between MTRasym and R2* between prostate cancer and prostatic hyperplasia. Higher diagnostic confidence could be achieved using APT together with mDIXON-Quant in differentiating prostate cancer and benign prostatic hyperplasia.
Table 2. Comparison o MTRasym and R2* values between the two groups
Figure1 and Figure 2